TRAW · Traws Pharma, Inc. · Executive Compensation
$0.56
+0.03 (+6.17%)
At close · Sep 11
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on current projections, the Company believes that it does not have sufficient cash and cash equivalents to support its operations for more than one year following the date that these financial statements are issued. As a result of these conditions, substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$8.67M
Shares
15.37M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Iain D. Dukes | CEO | $1,401,924 |
| Iain Dukes | D. Phil. Chief Executive Officer | $1,401,924 |
| Nikolay Savchuk | Ph.D. Chief Operating Officer | $734,810 |
| Werner Cautreels | Ph.D. Former Chief Executive Officer Charles Pauza Chief Science Officer | $353,897 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Werner Cautreels | Ph.D. Former Chief Executive Officer | $647,582 |
| Victor Moyo | M.D. Chief Medical Officer – Oncology | $478,436 |
| Steven M. Fruchtman | M.D. Former President and Chief Executive Officer Mark P. Guerin Former Chief Financial Officer and Chief Operating Officer | $410,000 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Steven M. Fruchtman | M.D. Former President and Chief Executive Officer Mark P. Guerin Former Chief Financial Officer and Chief Operating Officer | $1,106,747 |
| Mark P. Guerin | Chief Operating Officer and Chief Financial Officer | $745,518 |
| Victor Moyo | M.D. Chief Medical Officer – Oncology | $404,678 |
| Werner Cautreels | Ph.D. Former Chief Executive Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Steven M. Fruchtman | M.D. President and Chief Executive Officer | $1,326,782 |
| Mark P. Guerin | Chief Operating Officer and Chief Financial Officer | $844,699 |
| Mark S. Gelder | Chief Medical Officer | $677,638 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Steven M. Fruchtman | President and Chief Executive Officer | $2,674,213 |
| Mark P. Guerin | Chief Operating Officer and Chief Financial Officer | $1,299,520 |
| Abraham N. Oler | Senior Vice President, Corporate Development and General Counsel | $1,093,291 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Steven M. Fruchtman | President and Chief Executive Officer | $1,031,823 |
| Mark P. Guerin | Chief Financial Officer | $622,109 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Ramesh Kumar | Former President and Chief Executive Officer | $1,207,526 |
| Steven M. Fruchtman | President and Chief Executive Officer | $772,513 |
| Manoj Maniar | Senior Vice President, Product Development | $576,058 |
| Richard C. Woodman | Chief Medical Officer and Senior Vice President, Research and Development | $425,312 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Ramesh Kumar | Former President and Chief Executive Officer | $1,174,535 |
| Steven M. Fruchtman | President and Chief Executive Officer | $691,046 |
| Manoj Maniar | Senior Vice President, Product Development | $676,191 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Jack E. Stover | Director | Appointed | 2026-07-09 |
| Nikolay Savchuck Ph.D. | Director | Appointed | 2026-07-09 |
| M. Teresa Shoemaker | Director | Appointed | 2026-07-09 |
| Trafford Clarke, Ph.D. | Director | Appointed | 2026-07-09 |
| John Leaman, M.D. | Director | Appointed | 2026-07-09 |
| Werner Cautreels, Ph.D. | Director | Appointed | 2026-07-09 |
| Iain Dukes, D.Phil. | Director | Appointed | 2026-07-09 |
| Jack E. Stover | director | Appointed | 2025-11-28 |
| Nikolay Savchuck Ph.D. | director | Appointed | 2025-11-28 |
| M. Teresa Shoemaker | director | Appointed | 2025-11-28 |
| John Leaman, M.D. | director | Appointed | 2025-11-28 |
| Trafford Clarke, Ph.D. | director | Appointed | 2025-11-28 |
| Werner Cautreels, Ph.D. | director | Appointed | 2025-11-28 |
| Iain Dukes, D.Phil. | director | Appointed | 2025-11-28 |
| John Leaman, MD | independent director | Appointed | 2025-10-06 |
| Charles Parker | Interim Chief Financial Officer | Appointed | 2025-07-03 |
| Nora Brennan | Interim Chief Financial Officer | Resigned | 2025-07-03 |
| Jack Stover | Chairman | Appointed | 2025-04-18 |
| Iain Dukes | Interim Chief Executive Officer | Appointed | 2025-03-28 |
| Werner Cautreels | Chief Executive Officer | Retired | 2025-03-28 |
| Nora Brennan | Interim Chief Financial Officer | Appointed | 2025-02-07 |
| Mark Guerin | Chief Financial Officer | Resigned | 2025-02-07 |
| Luba Greenwood | member of the Board of Directors | Resigned | 2024-12-20 |
| Luba Greenwood | director | Appointed | 2024-09-17 |
| James J. Marino | director | Resigned | 2024-09-17 |
Key facts
CIK
1130598
CUSIP
68232V884
13F (30d)
26 filings
26 filers
Visit website
Investor relations